Grab Sources And More From The CMND Company Presentation.
-----
And as I mentioned above, CMND has several potential catalysts that could provide a breakout spark near term. Here they are:
No. 1 CMND Potential Catalyst - A Tiny Float Could Provide Access To Extreme Volatility
According to the Yahoo Finance website, CMND has a tiny float.
The website reports this profile to have approximately 1.17Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts (like big news) could spark a vertical move in the short-term.
-----
No. 2 CMND Potential Catalyst - Positive Results Signal Pre-Clinical Study Trending In Right Direction
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Co-caine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward process
Tel Aviv, Israel / Vancouver, Canada, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major under-treated health problems, today announced additional positive pre-clinical results in its ongoing series of research studies conducted to illuminate the tremendous potential of MEAI and its effect on substance-use-disorder (SUD). The latest in-vivo studies examined the effect of MEAI on the natural reward process as it pertains to co-caine addiction.
The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center at Bar Ilan University in Israel. As previously announced (see press release August 24, 2022), Clearmind's proprietary MEAI at a dose of 5mg/kg, demonstrated unique ability to decrease co-caine craving and potentially become the first dedicated co-caine addiction treatment.
The latest research studies were designed to evaluate the effects of MEAI on natural reward, as reward-based positive reinforcement is a shared evolutionary survival strategy across species. However, in drug addiction, reward seeking becomes maladaptive and endangers survival. The purpose of this in-vivo study, was to conclude whether MEAI uses the same mechanisms that underlie the seeking of both drug and natural rewards (such as sucrose). The results demonstrated that natural reward was maintained in the MEAI-treated rats, thus showing that the effect of MEAI on drug-seeking is not related to the general reward system.
“We are thrilled to continuously exhibit positive results of our proprietary drug candidate MEAI. The results of these latest in-vivo studies reinforce previous findings and demonstrate that MEAI may be an effective treatment addiction without negatively affecting natural reward," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “Co-caine is extremely addictive and there is currently no dedicated treatment. I believe Clearmind is leading the way in this field."
Professor Gal Yadid stated “Very interesting results were revealed in this set of in-vivo studies. The empirical data show that MEAI is a potential treatment for co-caine addiction, in particular, and SUD, in general. This observation is based on our experience and previous data from testing various treatments for SUD. Further studies are needed to better characterize the responding population.”
Read the full article here.
-----
No. 3 CMND Potential Catalyst - New Batch Of CMND-100 Manufactured For First In-Human Clinical Trial
Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.
The trial will evaluate the psych-e-delic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD).
“Having our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “Our pre-clinical positive results indicated the potential of our unique treatment for AUD. We continue to execute the final steps necessary in order to commence our clinical program.”
The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.
Read the full article here.
-----
No. 4 CMND Potential Catalyst - Company's Drug Candidate, MEAI, Could Treat Obesity And Metabolic Syndrome
Israel-Based Clearmind Medicine Shows Efficacy of Psych-e-delic- Derived Obesity Treatment in Pre-Clinical Trial
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity
Tel Aviv, Israel / Vancouver, Canada, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych-e-delic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome.
The study, conducted at the Hebrew University of Jerusalem, as part of a collaboration established with the university’s technology transfer company, Yissum, included multi-parameter metabolic assessments such as body weight, fat mass, glucose tolerance, insulin sensitivity, liver enzymes and fat accumulation as well as food consumption patterns. It included three groups of rodents: one was fed a standard diet, another a high-fat diet, and the third a high-fat diet group along with treatment with MEAI.
The animals treated with MEAI showed increased energy expenditure, better fat utilization and weight loss of 20%, while reducing their overall fat mass and preserving their lean body mass. No effect on motivation and well-being was observed. Additionally, MEAI treatment yielded normalization of insulin levels, improved glucose tolerance as well as reduced fat and triglycerides accumulation in the liver. These results were significantly better than those obtained in the high fat, untreated group.
Furthermore, a significant reduction in sucrose preference was observed following administration of MEAI for two days at the effective dose, supporting the notion that it can dampen the hedonic value of rewarding stimuli. Thus, MEAI may be beneficial for the treatment of compulsive reward-seeking behavior or excessive consumption of sweet foods.
"We’re very excited about these results, which suggest that MEAI may be effective in treating obesity, one of the world's most pressing problems," said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer “These additional positive results in our treatment of addictions, once again indicate MEAI’s potential to become a viable treatment for a variety of disorders.”
Dr. Adi Zuloff-Shani also noted that the global market for obesity drugs was valued by third-party sources in 2021 at $1.9Bn.
The study was led by Prof. Joseph Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research and Dr. Saja Baraghithy, Ph.D.
“While there is some evidence suggesting that psychedelic drugs, such as L-S-D and psi-lo-cybin, may be effective in treating obesity and other eating disorders, no solid experimental proof really exists, until now. We show for the first time that MEAI’s obesity effect works by altering various metabolic processes in the body, such as energy expenditure, fat storage and glucose utilization to promote weight loss,” said Prof. Tam. “These findings suggest that MEAI may be beneficial for reducing the risk of obesity-related complications, such as type 2 diabetes and fatty liver diseases.”
...
Read the full article here.
-----
No. 5 CMND Potential Catalyst - Nasdaq Uplisting Creates Incredible Exposure Opp.
Clearmind Medicine Announces Closing of $7.5Mn Public Offering and Uplisting to the Nasdaq Capital Market
VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), ..., today announced the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of $6.50 per share (CAD$8.65), for aggregate gross proceeds of $7.5Mn, prior to deducting underwriting discounts and offering expenses. The closing occurs following a 1-for-30 reverse st-ock split, which was effective at 5:30 p.m. on September 30, 2022.
...
Read the full article here.
Aegis Capital Corp. Acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ: CMND)
NEW YORK, NY / ACCESSWIRE / November 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $7.5Mn Underwritten Public Offering & Uplisting for Clearmind Medicine Inc. (NASDAQ:CMND).
Read the full article here.
-----
CMND Recap - The Top 5 Potential Breakout Catalysts For This Nasdaq Past Champ
No. 1 - A Tiny Float Could Provide Access To Extreme Volatility
No. 2 - Positive Results Signal Pre-Clinical Study Trending In Right Direction
No. 3 - New Batch Of CMND-100 Manufactured For First In-Human Clinical Trial
No. 4 - Company's Drug Candidate, MEAI, Could Treat Obesity And Metabolic Syndrome
No. 5 - Nasdaq Uplisting Creates Incredible Exposure Opp.
-----
Coverage is officially reinitiated on CMND. When time permits, do this:
